2026 Consensus and review of Lipoprotein(a) from Taiwan Society of Lipid and Atherosclerosis: Molecular pathogenesis, epidemiology, clinical implications, and advances in diagnostic strategies - PubMe
3 hours ago
- #Cardiovascular Disease
- #Diagnostic Advances
- #Lipoprotein(a)
- Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein that acts as an independent, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD).
- Structurally, Lp(a) consists of an LDL-like particle linked to apolipoprotein(a) [apo(a)], contributing to atherogenic, thrombogenic, and inflammatory properties, primarily through its role as a carrier of oxidized phospholipids (OxPL).
- Plasma Lp(a) concentrations are mainly influenced by genetic factors, specifically the number of kringle IV type 2 (KIV-2) repeats in the LPA gene, with lifestyle or environmental factors having minimal impact.
- In Taiwan and East Asia, clinical testing for Lp(a) is underutilized despite evidence linking elevated levels to increased cardiovascular risk, with local studies showing prognostic value for coronary artery disease and ischemic stroke.
- Barriers to Lp(a) recognition and management include limited physician awareness, implementation challenges, and therapeutic nihilism, highlighting the need for improved diagnostic strategies and risk management in Taiwan.